New hope: immunotherapy offers alternative to hormone therapy for some prostate cancer patients
NCT ID NCT04019964
Summary
This study tested whether the immunotherapy drug nivolumab could control prostate cancer recurrence without using hormone-blocking therapy. It involved 8 men whose prostate cancer had returned after initial treatment and who had specific genetic markers in their tumors. Researchers wanted to see if this drug could lower PSA levels and delay cancer progression as an alternative to standard hormone therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21287, United States
Conditions
Explore the condition pages connected to this study.